Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

NERV Relative to the S&P 500

NERV Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Minerva Neurosciences, Inc. (NASD:NERV) seasonal charts above shows that a Buy Date of April 24 and a Sell Date of September 18 has resulted in a geometric average return of 17.9% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 52.93% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It ?focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company’s pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson’s disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and?depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson’s disease.

To download NERV seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: NERV